Medical News Today: Is hair loss a side effect of Adderall?

Adderall is a combination drug for the short-term treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Although it is generally a safe and effective drug, it can cause a range of side effects. Alopecia, or hair loss, is a potential but uncommon side effect of taking Adderall. Learn more here.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: ADHD / ADD Source Type: news

Related Links:

Although intellectual disability was included in the first description of Duchenne muscular dystrophy (DMD), the cognitive and neurodevelopmental (ND) components of DMD and Becker muscular dystrophy (BMD) remain overshadowed by their motor, cardiac, and pulmonary manifestations. To assess the ND comorbidity burden in dystrophinopathy patients at Le Bonheur Children's Hospital neuromuscular clinic, abstraction of the electronic medical record was performed for 46 patients. Diagnoses of ADHD, epilepsy, autism spectrum, obsessive compulsive, oppositional defiant, mood, anxiety, and sleep disorders, along with discussion of an...
Source: Neuromuscular Disorders - Category: Neurology Authors: Source Type: research
HAIR loss is very normal, and we can lose between 50 and 100 hairs a day, often without noticing. Some types of hair loss are permanent, like male and female pattern baldness. Nonetheless, there are some ways to prevent thinning hair, according to a recent study.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Parents of children with ADHD typically report higher levels of parenting stress than parents of typically developing children. Children with ADHD display developmentally inappropriate levels of hyperactivity, impulsivity, and inattention. Some children wi...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
AbstractOrganisms have an evolutionarily conserved internal rhythm that helps them anticipate and adapt to daily changes in the environment. Synchronized to the light-dark cycle with a period of around 24 hours, the timing of the circadian clock is set by light-triggering signals sent from the retina to the suprachiasmatic nucleus. Other inputs, including food intake, exercise, and temperature, also affect clocks in peripheral tissues, including skin. Here, we review the intricate interplay between the core clock network and fundamental physiological processes in skin such as homeostasis, regeneration, immune and stress re...
Source: FEBS Letters - Category: Biochemistry Authors: Tags: Review Source Type: research
Translational Psychiatry, Published online: 18 September 2021; doi:10.1038/s41398-021-01604-3Machine-learning-based diagnosis of drug-naive adult patients with attention-deficit hyperactivity disorder using mismatch negativity
Source: Translational Psychiatry - Category: Psychiatry Authors: Source Type: research
This study constitutes the first observation of an increased density of PSD-93-CRH co-localized neurons in the hypothalamic paraventricular nucleus (PVN) of patients with major depression. PSD-93 overexpression in CRH neurons in the PVN induced depressi on-like behaviors in mice, accompanied by increased serum corticosterone level. PSD-93 knockdown relieved the depression-like phenotypes in a lipopolysaccharide (LPS)-induced depression model. Electrophysiological data showed that PSD-93 overexpression increased CRH neurons synaptic activity, while PSD-93 knockdown decreased CRH neurons synaptic activity. Furthermore, ...
Source: Acta Neuropathologica - Category: Neurology Source Type: research
Condition:   ADHD Intervention:   Behavioral: Attention Deficit Hyperactivity Disorder Treatment Decision Aid Sponsors:   Massachusetts General Hospital;   Center for Survey Research, University of Massachusetts, Boston Completed
Source: - Category: Research Source Type: clinical trials
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral presenta...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Gambling Disorder (GD) has been recently re-classified in the DSM-5 under the “substance-related and addictive disorders,” in light of its genetic, endophenotypic, and phenotypic resemblances to substance dependence. Diminished control is a core defining concept of psychoactive substance dependence or addiction and has given rise to the concept of “behavioral” addictions, which are syndromes analogous to substance addiction, but with a behavioral focus other than ingestion of a psychoactive substance. The main symptom clusters are represented by loss of control, craving/withdrawal, and neglect of ot...
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
More News: Adderall | ADHD | Alopecia | Health | Hyperactivity | Learning | Narcolepsy | Sleep Medicine | Universities & Medical Training